Antipsychotic induced hyperprolactinemia: synthesis of world wide guidelines and integrated recommendations for assessment, management and future research
RationaleHyperprolactinemia is a highly prevalent adverse effect of many antipsychotic agents, with potentially serious health consequences. Several guidelines have been developed for the management of this condition; yet, their concordance has not been evaluated.ObjectivesThe objectives of this paper were (1) to review current clinical guidelines; (2) to review key systematic evidence for management; and (3) based on our findings, to develop an integrated management recommendation specific to male and female patients who are otherwise clinically stabilised on antipsychotics.MethodsWe performed searches of Medline and EMBASE, supplemented with guideline specific database and general web searches, to identify clinical guidelines containing specific recommendations for antipsychotic induced hyperprolactinemia, produced/updated 01/01/2010 15/09/2016. A separate systematic search was performed to identify emerging management approaches described in reviews and meta analyses published 2010.ResultsThere is some consensus among guidelines relating to baseline PRL screening (8/12 guidelines) screening for differential diagnosis (7/12) and discontinuing/switching PRL raising agent (7/12) Guidelines otherwise diverge substantially regarding most aspects of screening, monitoring and management (e.g. treatment with dopamine agonists) There is an omission of clear sex specific recommendations. Systematic literature on management approaches is promising; more research is needed. An integrated management recommendation is presented to guide sex specific clinical response to antipsychotic induced hyperprolactinemia. Key aspects include asymptomatic hyperprolactinemia monitoring and fertility considerations with PRL normalisation.ConclusionFurther empirical work is key to shaping robust guidelines for antipsychotic induced hyperprolactinemia. The integrated management recommendation can assist clinician and patient decision making, with the goal of balancing effective psychiatric treatment while minimising PRL related adverse health effects in male and female patients.
Psychopharmacology